BioCentury | Jan 8, 2021
Emerging Company Profile

Impact founder Hood launches Endeavor with $62M to address pulmonary diseases

...the company may also test taladegib in patients with “long COVID” to address pulmonary dysfunction. Hood said taladegib...
...could involve exploring additional indications for taladegib and in-licensing additional compounds. COMPANY PROFILEEndeavor BioMedicinesSan Diego, Calif.Technology: Taladegib...
...Funds, Longitude Capital, Endeavor’s managementCEO: John HoodPatents: Multiple issued composition of matter patents on taladegib Danielle Golovin taladegib (LY2940680) Erivedge...
BioCentury | Mar 14, 2016
Company News

Ignyta cancer news

...focus on its molecularly targeted pipeline and reduce operating expenses. The company will focus entrectinib, taladegib...
...anaplastic lymphoma kinase (ALK) . Next half, Ignyta plans to begin Phase II testing of taladegib...
BioCentury | Feb 22, 2016
Clinical News

Taladegib: Phase I started

...evaluate oral taladegib plus weekly paclitaxel. Ignyta has exclusive, worldwide rights to develop and commercialize taladegib...
...Inc. (NASDAQ:RXDX), San Diego, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Taladegib ( LY2940680...
BioCentury | Nov 23, 2015
Company News

Eli Lilly, Ignyta deal

...Lilly granted Ignyta exclusive, worldwide rights to develop and commercialize oral and topical taladegib ( LY2940680...
...plus royalties. Ignyta also granted Lilly exclusive rights to develop and commercialize combination products containing taladegib...
...issued Lilly 1.5 million shares of stock at $20 per share in a private placement. Taladegib...
BioCentury | Nov 10, 2011
Distillery Therapeutics

Indication: Pulmonary disease

...Phase II and Phase I trials to treat cancer. Eli Lilly and Co.'s SMO antagonist LY2940680...
BioCentury | May 5, 2011
Distillery Therapeutics

Indication: Cancer

...in Phase I testing to treat advanced solid tumors. Eli Lilly and Co.'s SMO antagonist LY2940680...
BioCentury | Apr 18, 2011
Clinical News

Eli Lilly preclinical data

...In a mouse model of medulloblastoma, oral LY2940680 significantly improved survival vs. controls. The small molecule...
...Association for Cancer Research meeting in Orlando. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: LY2940680...
Items per page:
1 - 7 of 7